The Food and Drug Administration (FDA) has been promoting an active return to recruitment following a major staffing upheaval in April 2025. The source reports that Elon Musk’s U.S. DOGE Service enacted deep cuts at that time — roughly 3,500 workers were removed — which precipitated a broader exodus of agency staff. Agency leaders have publicly signaled recovery: they highlight new employees with group photos and announcements and have told external audiences that hiring is underway.
The reporting cites director-level comment from Karim Mikhail of the FDA’s Center for Biologics Evaluation and Research saying the agency is “very actively hiring,” and references reporting that the FDA is seeking to add more than 2,000 workers. Those public-facing comments and imagery are part of the agency’s effort to communicate that rebuilding is in progress.
STAT reports that beneath the upbeat messaging there are operational constraints tied directly to the earlier DOGE-era staffing reductions. The article states that the same cuts the FDA is attempting to reverse have left its human-resources capacity diminished, producing bureaucratic slowdowns in hiring processes.
Specifically, the piece describes a centralized hiring center as short-staffed and struggling to keep pace with the volume of recruitment the agency is trying to execute. That reduced HR capacity is presented as a practical obstacle to rapidly restoring the agency’s pre-cut workforce levels, and as a source of administrative delays for onboarding and processing new hires.
Despite the administrative bottlenecks, several concrete signs of resumed hiring are noted in the article excerpt. Agency leaders are publicly celebrating onboarded staff, and agency officials have told industry audiences that recruitment has accelerated. The reporting also cites external coverage that quantified the agency’s hiring plans (more than 2,000 hires) as evidence the FDA is attempting a substantial recovery effort.
These signals—public statements by leaders, social media welcome posts, and reporting of planned hiring numbers—constitute the visible evidence STAT presents that the FDA is moving to rebuild its workforce.
STAT frames the situation as a contrast between the FDA’s public narrative and the internal operational picture. On one hand, FDA leaders and communications show photos and issue statements signaling progress. On the other hand, the agency’s HR functions, diminished by the DOGE-era cuts, are reportedly creating bureaucratic friction that slows the actual hiring trajectory.
The article positions these HR capacity problems as a new challenge in the broader rebuilding effort: an administrative constraint that complicates recruitment despite senior leadership’s reported intent and activity.
The excerpt available from the source provides an overview and several named elements (the April 2025 DOGE cuts of roughly 3,500 jobs; comments from Karim Mikhail; reporting that the agency is recruiting more than 2,000 employees; characterization of the centralized hiring center as short-staffed). However, the source excerpt does not include a full account of the reporting. Important operational specifics were not reported in the visible portion of the article, including:
Those additional details are not present in the provided source text and appear to be part of the material behind the STAT+ paywall. The source therefore offers a reliable summary of the high-level problem—public hiring ambitions hampered by reduced HR capacity from prior cuts—but does not supply the operational depth or data necessary to fully document the scale, timeline, or specific corrective measures.
Summary
The available reporting presents a clear, limited account: after a drastic reduction of staff under DOGE in April 2025, the FDA is publicly promoting that it is hiring again and intends to add a large number of employees. At the same time, the agency’s human-resources capacity, including a centralized hiring center, is reported to be short-staffed and producing bureaucratic delays that impede the speed of rebuilding. The article excerpt stops short of granular operational data, and the remainder of the story that may contain additional specifics was not included in the source provided.